SLU-PP-332: A Promising ERR Agonist for Exercise Mimetic Applications

Research brief

SLU-PP-332, an ERR agonist, enhances exercise capacity and metabolic benefits in preclinical models [Billon et al., 2024][Okda HE et al., 2026]. The compound induces gene expression changes and boosts mitochondrial function [de Souza-Lima J et al., 2026][Billon C et al., 2023].

Key findings

• SLU-PP-332 is a potent ERR agonist with promising exercise mimetic capabilities [Billon C et al., 2024]. • Enhances mitochondrial function and endurance in preclinical models [Billon C et al., 2023]. • Improves metabolic parameters like glycemic control and fat reduction [Billon et al., 2024]. • Described as an effective tool for ERR-driven therapeutic exploration [Okda HE et al., 2026]. • Requires further human trials for safety and efficacy confirmation [de Souza-Lima J et al., 2026].

Detailed research context

Introduction and Study Context

SLU-PP-332 is receiving considerable attention for its role as an estrogen-related receptor (ERR) agonist with exercise mimetic properties. ERRs, including ERRα, ERRβ, and ERRγ, are critical in regulating mitochondrial metabolism and gene expression associated with exercise adaptations [Billon C et al., 2023; de Souza-Lima J et al., 2026]. This article aims to explore the capabilities of SLU-PP-332 and its analogues in potentially mimicking exercise-induced benefits as evidenced in preclinical models.

Mechanisms of Action

SLU-PP-332 activates ERRs, primarily ERRα, inducing gene expression profiles similar to those initiated by acute aerobic exercise. This includes upregulation of Ddit4 and Slc25a25, which are crucial for enhancing cellular respiration and mitochondrial function [Okda HE et al., 2026; Billon C et al., 2023]. Moreover, specific structural features have been identified that control its potency and transcriptional efficacy [Okda HE et al., 2026].

Efficacy in Preclinical Models

Research has demonstrated that SLU-PP-332 significantly increases mitochondrial function, enhances type IIa muscle fibers, and improves endurance in mice, simulating exercise-inducible outcomes without physical exertion [Billon C et al., 2023]. Also noted is the compound’s ability to reduce adiposity and improve glycemic control, making it promising for managing obesity and metabolic syndrome [de Souza-Lima J et al., 2026; Billon et al., 2024].

Comparative Analysis with Analogues

The development of SLU-PP-915, a chemically distinct analogue that retains the ERR agonist properties, has expanded the context of research. SLU-PP-915 is orally bioavailable and maintains efficacy similar to SLU-PP-332, offering an advanced tool for exploring chronic therapeutic potential [Billon C et al., 2026]. This diversification in ERR agonists provides a robust platform for evaluating the therapeutic scope of pharmacological activation.

Current Limitations and Future Directions

Despite promising results, further research is required to understand the long-term safety and effectiveness of SLU-PP-332 and its analogues in human populations. Current studies have predominantly used animal models, emphasizing a gap in clinical data that needs to be addressed before therapeutic application [de Souza-Lima J et al., 2026]. Research inquiries could focus on the translational potential of these findings into human models, as well as investigating potential off-target effects or adverse outcomes in extended usage scenarios.

Conclusion

SLU-PP-332 stands as a compelling candidate in the realm of pharmacological exercise mimetics, with significant capacity to enhance metabolic function and physical endurance as demonstrated in preclinical models. However, human studies are necessary to verify these benefits and ensure safety, paving the way for new therapeutic options in metabolic disorders and other exercise-responsive conditions.

Source method

This research briefing is based on the verified PubMed records linked in the References & Citations section below.